Gossamer Bio, Inc. — Form SCHEDULE 13D/A
Filed October 8, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
▼ Likely negative
significance 28/100
What the filing says
Between September 29 and October 8, 2026, D.E. Shaw Co., L.P., D.E. Shaw Co., L.L.C., Valence Portfolios L.L.C., and David E. Shaw (via Cogence and Valence vehicles) sold approximately 24,000 common shares at prices ranging from $9.87 to $12.34 per share, totaling roughly $260K–$275K in aggregate proceeds. The filing updates a Schedule 13D with transaction details and refreshed powers of attorney for regulatory filings.
Why this rating
Insider selling of ~$270K is ~0.1% of $271M market cap—routine portfolio rebalancing. No change in control stake disclosed; sells are small and spread over 10 days at declining prices—consistent with ordinary liquidation, not strategic signal. Negative sentiment from selling but magnitude immaterial to business.
See more from October 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.